This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FLNB / Filamin-B · IHC design guide
Design Immunohistochemistry for FLNB
Plan FLNB staining in paraffin sections using its cytoplasmic and membranous tissue pattern and abundant endothelial signal (HPA tissue IHC). This guide covers fixation, antibody selection, chromogenic detection and interpretation, with isoform expression as a consideration (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
FLNB Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous in most cells (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic and membranous; abundant in endothelium (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02562-1) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Caudate+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A02562-1) | |
| Caveat | Abundant endothelial staining may obscure weaker cells (HPA tissue IHC) | |
| Regulation | Isoform expression varies by tissue (UniProt) | |
| Isoform / epitope | 9 isoforms; check splice-region epitope coverage (UniProt) |
Section 1
Recommended FLNB IHC & IF Protocols
The catalog antibody protocol is paired with a published IHC protocol for human PDAC sections (PMC7611572).
| Sample | Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet A02562-1) |
| Fixation | Image fixative and duration unreported (datasheet A02562-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02562-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02562-1) |
| Primary antibody | Rabbit anti-FLNB, 1-2 μg/ml (datasheet A02562-1) |
| Primary incubation | Overnight at 4 °C (datasheet A02562-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A02562-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | FLNB-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in most cells. Highly abundant in endothelial cells. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval (datasheet A02562-1); the published protocol does not specify its retrieval conditions (PMC7611572).
Section 2
What Is the Expected FLNB Staining Pattern?
FLNB is a cytoplasmic, cortical and cytoskeletal protein with no transmembrane segment (UniProt O75369 localization and topology). In paraffin sections, expect cytoplasmic and membranous staining in many cell types, especially abundant signal in endothelial cells (HPA tissue IHC). HPA rates the tissue profile Enhanced, with medium agreement between staining and RNA data and support from paired antibodies (HPA tissue IHC reliability).
| Cytoplasmic and cell-edge signal appears in endothelial cells and glandular epithelium. | This fits the reported distribution: endothelial cells are highly abundant, while glandular cells score High in adrenal gland, appendix, breast, colon and other listed tissues (HPA tissue IHC). Judge the stained cell population as well as intensity; a positive vessel does not make every neighboring cell positive (HPA tissue IHC). |
| A sharp nuclear-only pattern appears, without convincing cytoplasmic or cell-edge staining. | Treat this as a localization mismatch requiring investigation, rather than a confirmed FLNB pattern: UniProt places FLNB in the cytoplasm, cortex and cytoskeleton, while HPA reports cytoplasmic and membranous tissue staining (UniProt O75369 localization; HPA tissue IHC). Check antibody specificity and detection background (general IHC practice). |
| Strong signal appears in a cell population reported as undetected, such as cardiomyocytes or germinal center cells. | Question specificity or endogenous detection activity before calling these cells FLNB-positive (HPA: Not detected in cardiomyocytes and germinal center cells; general IHC practice). Interpret the named cell type, not the whole tissue: other cells in the section may stain (HPA tissue IHC). |
| Color spreads across extracellular space or appears uniformly across unrelated cells. | Diffuse deposition obscures the expected cell-associated distribution (HPA tissue IHC; UniProt O75369 localization). Review blocking, washes, antibody concentration and the detection-only control for nonspecific or endogenous signal (general IHC practice). Do not score this haze as positive FLNB staining (general IHC practice). |
| No staining appears in a section containing an expected positive population. | First verify that the positive population is actually present: HPA reports abundant endothelial staining and High glandular staining in several listed tissues (HPA tissue IHC). If those cells are present but blank, check the IHC workflow and antibody performance with a validated positive control (general IHC practice). |
💡Expected FLNB appearanceCall a convincing positive result when cell-associated cytoplasmic and membranous staining includes abundant endothelial signal or High-staining glandular cells where expected; nuclear-only color or diffuse extracellular haze is suspect (HPA tissue IHC; UniProt O75369 localization; general IHC practice).
| Cell population and tissue | HPA reports cytoplasmic and membranous expression in most cells, with especially abundant endothelial staining, but its listed intensities vary by cell type (HPA tissue IHC). For example, skeletal myocytes are Low and cardiomyocytes are Not detected; do not turn a tissue-level positive into an expectation for every cell (HPA tissue IHC). |
| Antibody validation | Two listed rabbit polyclonal antibodies, HPA004747 and HPA004886, have Enhanced IHC validation; CAB019322 is Supported for IHC (HPA antibodies). Enhanced supports the reported profile through agreement between independent antibodies or orthogonal evidence, but does not guarantee the same pattern from an unvalidated reagent (HPA antibody-validation summary). |
| Isoform interpretation | UniProt lists 9 FLNB isoforms and tissue-dependent isoform expression (UniProt O75369 isoforms and tissue specificity). The supplied antibody data give no epitope mapping, so staining cannot identify an isoform or establish that every isoform is detected (UniProt O75369; HPA antibodies). |
| Heart muscle interpretation | UniProt reports FLNB isoform expression in heart, whereas HPA reports cardiomyocytes as Not detected by tissue IHC (UniProt O75369 tissue specificity; HPA: Not detected in cardiomyocytes). These observations refer to different measurement contexts; do not use the UniProt statement alone to demand a positive cardiomyocyte stain. |
| IF/ICC question: where should FLNB appear? | In ICC-IF, HPA places FLNB mainly at the plasma membrane, with additional Golgi, actin-filament and cytosolic localization (HPA subcellular ICC-IF). This is a localization reference for the separate IF/ICC guide, not an IHC-P protocol or a requirement that every compartment be visible in tissue sections. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected endothelial or glandular cells are present, but the stain is blank. | The positive population expected from the tissue profile is absent from the result (HPA tissue IHC). A failed staining or detection step is possible (general IHC practice). | Confirm section identity and cell preservation, then check antibody incubation, retrieval conditions and detection with a known positive section (general IHC practice). No FLNB-specific retrieval condition is supplied. |
| A section appears negative because its cardiomyocytes do not stain. | Cardiomyocytes are listed as Not detected by HPA tissue IHC, despite UniProt reporting heart isoform expression (HPA: Not detected in cardiomyocytes; UniProt O75369 tissue specificity). | Assess endothelial and other identifiable cells separately; use a listed High-staining glandular population as a positive reference when available (HPA tissue IHC). |
| Strong color is confined to nuclei. | The compartment conflicts with cytoplasmic, cortical and cytoskeletal localization and with the HPA tissue profile (UniProt O75369 localization; HPA tissue IHC). | Compare a detection-only control and a second IHC-validated antibody, then reassess whether cytoplasmic or membranous signal is present (general IHC practice; HPA antibodies). |
| Chromogen appears in cells HPA lists as Not detected. | Cross-reactivity or endogenous detection activity may explain a discordant cell-type pattern; neither is established by the image alone (HPA tissue IHC; general IHC practice). | Use a detection-only control, inspect tissue pigment and compare the pattern with an independently validated antibody (general IHC practice; HPA antibodies). |
| The whole section has diffuse color that prevents cell-by-cell scoring. | Excess reagent signal, incomplete washing or endogenous detection activity can produce background (general IHC practice). | Review blocking and washes, titrate the antibody and detection reagents, and score FLNB only after cell-associated signal is distinguishable (general IHC practice; HPA tissue IHC). |
| Cell-edge staining is seen, but fine actin-associated detail is unclear. | HPA tissue IHC describes broad cytoplasmic and membranous staining, while actin filaments are an additional ICC-IF location (HPA tissue IHC; HPA subcellular ICC-IF). | Score the IHC section against its tissue and cell-type pattern; consult the separate IF/ICC guide if filament-level localization is the experimental question (HPA tissue IHC; HPA subcellular ICC-IF). |
Experiment evidence
IHC & IF images showing FLNB staining
A02562-1 · IHCIHC analysis of Filamin B/FLNB using anti-Filamin B/FLNB antibody (A02562-1). Filamin B/FLNB was detected in a paraffin-embedded section of
A02562-1 · IHCIHC analysis of Filamin B/FLNB using anti-Filamin B/FLNB antibody (A02562-1). Filamin B/FLNB was detected in a paraffin-embedded section of
A02562-1 · IFIF analysis of Filamin B/FLNB using anti-Filamin B/FLNB antibody (A02562-1). Filamin B/FLNB was detected in an immunocytochemical section of
M02562-1 · IHCIHC analysis of Filamin B/FLNB using anti-Filamin B/FLNB antibody (M02562-1). Filamin B/FLNB was detected in a paraffin-embedded section of
M02562-1 · IHCIHC analysis of Filamin B/FLNB using anti-Filamin B/FLNB antibody (M02562-1). Filamin B/FLNB was detected in a paraffin-embedded section of
M02562-1 · IFIF analysis of Filamin B/FLNB using anti-Filamin B/FLNB antibody (M02562-1). Filamin B/FLNB was detected in an immunocytochemical section of
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000136068-FLNB/tissue/cerebral+cortex#imid_1781568
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000136068-FLNB/tissue/colon#imid_1781494
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000136068-FLNB/tissue/liver#imid_1781495
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000136068-FLNB/tissue/pancreas#imid_1781462
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB019322; green = FLNB, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB019322; green = FLNB, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for FLNB IHC & IF
🧪Run colon first: its glandular cells should stain (HPA: High in colon glandular cells). Use caudate glial cells as the negative tissue comparator (HPA: Not detected in caudate glial cells); on the colon slide, internal background comparators should show no specific cell-associated staining, but the supplied HPA row does not identify a named negative cell type there.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Caudate (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show FLNB in A-431, U-251MG, U2OS, with annotated localisation: Plasma membrane (supported) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and matched rabbit IgG isotype controls (selected-SKU caption: rabbit primary antibody), plus FLNB-knockout material as a biological negative where available. For chromogenic detection, quench endogenous peroxidase and assess endogenous biotin background when using the caption’s biotin-based detection system (selected-SKU caption: biotinylated secondary and streptavidin–biotin complex).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported; the selected-SKU paraffin-section caption does not state a fixative (selected-SKU caption: fixative unreported). Heat retrieval in EDTA at pH 8.0 is a documented starting condition, but retrieval dependence is unreported (selected-SKU caption: EDTA retrieval). Frozen-section suitability and whether IF is easier are unreported; for colon, distinguish cell-associated staining from luminal or edge background when scoring (HPA: High in colon glandular cells).
HPA tissue IHC evidence for FLNB
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Paired antibodies with high similarity supports the protein expression profile.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Hippocampus | Glial cells | Not detected | Protein (IHC) | HPA → |
| Lymph node | Germinal center cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced FLNB IHC Tips
Troubleshoot FLNB staining in paraffin sections by checking retrieval, tissue handling, cell compartment and controls before interpreting chromogenic signal.
Which retrieval conditions should I use when FLNB staining is weak?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A02562-1). Keep heating, cooling and section thickness consistent across the test and control slides so that differences in staining can be attributed to the variable under study. The documented tissue image used this retrieval before incubation with 2 μg/ml primary antibody overnight at 4°C (datasheet A02562-1). If staining remains weak, compare a small retrieval time series while checking section integrity and nonspecific staining; no alternate buffer is established for this antibody in the supplied evidence. Score cell type and compartment, because FLNB staining can be cytoplasmic and membranous (HPA tissue IHC).
How should I troubleshoot fixation-related loss of FLNB signal?
The selected paraffin-section caption does not state a fixative, so target-specific FLNB sensitivity to fixation is unknown (datasheet A02562-1). Record the fixative, fixation duration and tissue-processing history for each specimen, then compare weak and strong sections processed under matched conditions. Begin troubleshooting with the documented EDTA retrieval at pH 8.0 and the documented 2 μg/ml overnight primary incubation before changing several variables together (datasheet A02562-1). Include a same-run positive control and assess whether weak staining is widespread or confined to poorly preserved areas. Do not infer fixation performance from the reported tissue-expression pattern (HPA tissue IHC).
Should FLNB appear at the membrane or in the cytoplasm?
Expect cytoplasmic and membranous staining in many cell types, with particularly abundant staining in endothelial cells (HPA tissue IHC). FLNB also associates with the cell cortex, cytoskeleton and stress fibers, while its recorded topology has no transmembrane segment (UniProt O75369 localisation and topology). Thus, a peripheral chromogenic rim may reflect cortical FLNB; morphology alone cannot establish that the protein spans the membrane. Compare the suspected signal with adjacent cytoplasm and vascular cells at the same magnification, using a matched negative control to judge diffuse DAB haze. Strong nuclear-only staining warrants review of the antibody and detection controls because it does not match the supplied localisation evidence (UniProt O75369 localisation; HPA tissue IHC).
Can this IHC result distinguish FLNB isoforms or modified epitopes?
No isoform-specific or modification-specific epitope is supplied for the catalog antibody, so its chromogenic staining cannot by itself assign an FLNB isoform or phosphorylation state. FLNB has 9 recorded isoforms and multiple modified residues, including phosphothreonine at position 216 and phosphoserine at position 730 (UniProt O75369 isoforms and modified residues). If isoform identity matters, obtain the antibody epitope and compare it with the relevant isoform sequences before interpreting staining differences. Keep retrieval and incubation matched when comparing samples, since altered accessibility could mimic altered abundance. Report the result as FLNB immunoreactivity unless antibody specificity for the proposed isoform or modification has been established independently.
How can IF help resolve ambiguous FLNB staining in paraffin sections?
Use IF on a parallel section to test whether the FLNB pattern tracks the cells and structures suggested by chromogenic IHC, while treating IF conditions as a separate optimisation. Multiplex FLNB with an endothelial marker when assessing the prominent endothelial signal reported in tissue (HPA tissue IHC). Choose spectrally separated fluorophores and an emission channel with low tissue autofluorescence, then inspect single-stain and no-primary controls before interpreting overlap. If the epitope is cytoplasmic or on the inner cortical side, optimise permeabilisation; FLNB has no transmembrane segment, so a peripheral IF outline does not imply an extracellular epitope (UniProt O75369 topology and localisation). The supplied IHC caption provides no IF fixation or permeabilisation conditions (datasheet A02562-1).
What should I check when FLNB DAB staining looks diffuse?
First compare a no-primary control with the test section under identical development and counterstaining conditions. The documented chromogenic workflow uses a biotinylated secondary antibody, a streptavidin–biotin complex and DAB, so check endogenous peroxidase activity and potential biotin-related background as general detection controls (datasheet A02562-1; standard IHC practice). Confirm that the serum block and antibody incubation were applied consistently; the documented section used 10% goat serum and 2 μg/ml primary antibody overnight at 4°C (datasheet A02562-1). Examine whether haze follows tissue folds, damaged edges or empty spaces rather than recognizable cells. Preserve credible cytoplasmic and membranous staining when adjusting detection strength (HPA tissue IHC).
How should I score FLNB staining across specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored cell population and compartment before reviewing groups, because FLNB can stain cytoplasm and membrane and is highly abundant in endothelial cells (HPA tissue IHC). For cellular expression, record the percentage of positive cells and an intensity category, or calculate an H-score on a 0–300 scale using the percentages at intensities 0–3 (standard IHC scoring practice). For vascular staining, quantify positive vessel area or density per mm² of evaluable tissue and state the denominator. Exclude folds, necrosis and section edges using the same rules for every specimen. Keep retrieval, imaging, DAB development and thresholds matched across comparisons.
How do I separate true FLNB staining from artefact?
A credible result follows cell boundaries or cytoplasm in intact cells and may be conspicuous in endothelium, consistent with the reported tissue pattern (HPA tissue IHC). Peripheral staining can fit FLNB’s cell-cortex association, but an isolated nuclear-only pattern conflicts with the supplied localisation evidence (UniProt O75369 localisation; HPA tissue IHC). Review the no-primary control and examine whether apparent positives cluster at section edges, folds or necrotic regions, where staining artefacts commonly arise (standard IHC practice). Exclude residual endogenous enzyme signal before calling DAB deposits target positive, particularly when cellular structure is unclear. Interpret absent signal by cell type: cardiomyocytes are reported as not detected despite FLNB’s broader tissue distribution (HPA tissue IHC; UniProt O75369 tissue specificity).
Boster reagents
Best FLNB / Filamin-B IHC Antibodies
Both anti-FLNB antibodies have human paraffin-section IHC images and IF/ICC cell images; A02562-1 also lists mouse and rat reactivity (catalog applications, reactivity and image captions).
Real IHC data
Anti-Filamin B/FLNB Antibody ®
Cat # A02562-1
Real IHC data
Anti-Filamin B/FLNB Antibody ® (monoclonal, 11E2D2)
Cat # M02562-1
A02562-1 has IHC images from human lung cancer, mammary cancer, placenta and rectal cancer sections, plus an IF/ICC image from U2-OS cells (A02562-1 image captions). M02562-1 has IHC images from human lung cancer, rectal-cancer lymph node, renal-pelvis squamous metaplasia and spleen sections, plus an IF/ICC image from HeLa cells (M02562-1 image captions).
Which to pick: For human tissue IHC, either SKU has its own paraffin-section lung cancer image using EDTA retrieval at pH 8.0 and DAB detection; neither caption reports the fixative (A02562-1 and M02562-1 IHC captions). For IF/ICC, choose by host or cell-image precedent: rabbit A02562-1 is shown in U2-OS cells, while mouse monoclonal M02562-1, clone 11E2D2, is shown in HeLa cells (catalog host/clone and IF captions). For mouse or rat tissue IHC, choose A02562-1 based on its listed species reactivity and IHC application; its supplied IHC images show human tissue (A02562-1 catalog reactivity/applications and IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O75369 (FLNB_HUMAN, Filamin-B).
- Human Protein Atlas. FLNB tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. FLNB subcellular location (ICC-IF): Mainly localized to the plasma membrane. In addition localized to the Golgi apparatus, cytosol and actin filaments..
- Human Protein Atlas. FLNB antibody validation summary (3 antibodies).
- Single-cell-resolved differentiation of human induced pluripotent stem cells into pancreatic duct-like organoids on a microwell chip. Nature biomedical engineering 2021 — PMC7611572.
- The molecular basis of force selectivity by PIEZO2. Nature 2026 — PMC13149025.
- Biallelic pathogenic variants in FLNB are associated with paediatric steroid-resistant nephrotic syndrome via podocyte cytoskeletal dysfunction. Journal of medical genetics 2026 — PMC13539846.
- TGFβ and BMP Dependent Cell Fate Changes Due to Loss of Filamin B Produces Disc Degeneration and Progressive Vertebral Fusions. PLoS genetics 2016 — PMC4809497.
- PubMed PMID:9651345 — UniProt-cited evidence.
- PubMed PMID:9694715 — UniProt-cited evidence.
- PubMed PMID:11807098 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for FLNB (Filamin-B). Expected localisation Cytoplasmic and membranous in most cells (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02562-1). Validated IHC antibody: A02562-1 at 1-2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Caudate. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet A02562-1); 2. Fixation: Image fixative and duration unreported (datasheet A02562-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02562-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02562-1); 8. Primary antibody: Rabbit anti-FLNB, 1-2 μg/ml (datasheet A02562-1); 9. Primary incubation: Overnight at 4 °C (datasheet A02562-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A02562-1); Caveat: Abundant endothelial staining may obscure weaker cells (HPA tissue IHC); Isoform / epitope: 9 isoforms; check splice-region epitope coverage (UniProt); Regulation: Isoform expression varies by tissue (UniProt). Evidence: UniProt O75369, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the plasma membrane. In addition localized to…, Datasheet A02562-1, PMC7611572. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/FLNB/immunohistochemistry-ihc-guide.